| [1] |
R.L. Siegel, K.D. Miller, N.S. Wagle, A. Jemal. Cancer statistics, 2023. CA Cancer J Clin, 73 (1) (2023), pp. 17-48
|
| [2] |
F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68 (6) (2018), pp. 394-424
|
| [3] |
J. Remon, B. Besse, J.C. Soria. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. BMC Med, 15 (1) (2017), p. 55
|
| [4] |
D.O. Ochwang’i, C.N. Kimwele, J.A. Oduma, P.K. Gathumbi, J.M. Mbaria, S.G. Kiama. Medicinal plants used in treatment and management of cancer in Kakamega County, Kenya. J Ethnopharmacol, 151 (3) (2014), pp. 1040-1055
|
| [5] |
Z. Yan, Z. Lai, J. Lin. Anticancer properties of traditional Chinese medicine. Comb Chem High Throughput Screen, 20 (5) (2017), pp. 423-429
|
| [6] |
S. Jiwajinda, V. Santisopasri, A. Murakami, M. Kawanaka, H. Kawanaka, M. Gasquet, et al. In vitro anti-tumor promoting and anti-parasitic activities of the quassinoids from Eurycoma longifolia, a medicinal plant in southeast Asia. J Ethnopharmacol, 82 (1) (2002), pp. 55-58
|
| [7] |
Z.K. Duan, Z.J. Zhang, S.H. Dong, Y.X. Wang, S.J. Song, X.X. Huang. Quassinoids: phytochemistry and antitumor prospect. Phytochemistry, 187 (2021), Article 112769
|
| [8] |
G. Fiaschetti, M.A. Grotzer, T. Shalaby, D. Castelletti, A. Arcaro. Quassinoids: from traditional drugs to new cancer therapeutics. Curr Med Chem, 18 (3) (2011), pp. 316-328
|
| [9] |
S.M. Kupchan, R.W. Britton, M.F. Ziegler, C.W. Sigel. Bruceantin, a new potent antileukemic simaroubolide from Brucea antidysenterica. J Org Chem, 38 (1) (1973), pp. 178-179
|
| [10] |
C.L. Wiseman, H.Y. Yap, A.Y. Bedikian, G.P. Bodey, G.R. Blumenschein. Phase II trial of bruceantin in metastatic breast carcinoma. Am J Clin Oncol, 5 (4) (1982), pp. 389-391
|
| [11] |
J.C. Arseneau, J.M. Wolter, M. Kuperminc, J.C. Ruckdeschel. A phase II study of bruceantin (NSC-165, 563) in advanced malignant melanoma. Invest New Drugs, 1 (3) (1983), pp. 239-242
|
| [12] |
J. Xie, Z. Lai, X. Zheng, H. Liao, Y. Xian, Q. Li, et al. Apoptotic activities of brusatol in human non-small cell lung cancer cells: involvement of ROS-mediated mitochondrial-dependent pathway and inhibition of Nrf2-mediated antioxidant response. Toxicology, 451 (2021), Article 152680
|
| [13] |
M. Zhao, S.T. Lau, P.S. Leung, C.T. Che, Z.X. Lin. Seven quassinoids from Fructus Bruceae with cytotoxic effects on pancreatic adenocarcinoma cell lines. Phytother Res, 25 (12) (2011), pp. 1796-1800
|
| [14] |
P. Zhange, W. Tao, C. Lu, L. Fan, Q. Jiang, C. Yang, et al. Bruceine A induces cell growth inhibition and apoptosis through PFKFB4/GSK3β signaling in pancreatic cancer. Pharmacol Res, 169 (2021), Article 105658
|
| [15] |
N.N. Win, T. Ito, K.T. Ismail, Y.Y. Win, M. Tanaka, et al. Picrajavanicins H-M, new quassinoids from Picrasma javanica collected in Myanmar and their antiproliferative activities. Tetrahedron, 72 (5) (2016), pp. 746-752
|
| [16] |
Z.Q. Lai, S.P. Ip, H.J. Liao, Z. Lu, J.H. Xie, Z.R. Su, et al. Brucein D, a naturally occurring tetracyclic triterpene quassinoid, induces apoptosis in pancreatic cancer through ROS-associated PI3K/AKT signaling pathway. Front Pharmacol, 8 (2017), p. 936
|
| [17] |
M. Sonlimar, I. Dwiprahasto, J. Mustofa. Spectroscopic analysis and cytotoxic activity of quassinoid isolated from the seeds of Brucea javanica on Hela cell. Indones J Pharm, 22 (2) (2011), pp. 137-143
|
| [18] |
S.J. Moon, B.C. Jeong, H.J. Kim, J.E. Lim, H.J. Kim, G.Y. Kwon, et al. Bruceantin targets HSP 90 to overcome resistance to hormone therapy in castration-resistant prostate cancer. Theranostics, 11 (2) (2021), pp. 958-973
|
| [19] |
J.H. Liu, N. Zhao, G.J. Zhang, S.S. Yu, L.J. Wu, J. Qu, et al. Bioactive quassinoids from the seeds of Brucea javanica. J Nat Prod, 75 (4) (2012), pp. 683-688
|
| [20] |
H. Chen, J. Bai, Z.F. Fang, S.S. Yu, S.G. Ma, S. Xu, et al. Indole alkaloids and quassinoids from the stems of Brucea mollis. J Nat Prod, 74 (11) (2011), pp. 2438-2445
|
| [21] |
J. Fan, D. Ren, J. Wang, X. Liu, H. Zhang, M. Wu, et al. Bruceine D induces lung cancer cell apoptosis and autophagy via the ROS/MAPK signaling pathway in vitro and in vivo. Cell Death Dis, 11 (2) (2020), p. 126
|
| [22] |
P. Chumkaew, T. Srisawat. Antimalarial and cytotoxic quassinoids from the roots of Brucea javanica. J Asian Nat Prod Res, 19 (3) (2017), pp. 247-253
|
| [23] |
J. Zhou, J. Hou, J. Wang, J. Wang, J. Gao, Y. Bai. Brusatol inhibits laryngeal cancer cell proliferation and metastasis via abrogating JAK2/STAT3 signaling mediated epithelial-mesenchymal transition. Life Sci, 284 (2021), Article 119907
|
| [24] |
C. Cheng, F. Yuan, X.P. Chen, W. Zhang, X.L. Zhao, Z.P. Jiang, et al. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C. Biomed Pharmacother, 142 (2021), Article 111652
|
| [25] |
H. Chen, T. Jiang, H. Chen, J. Su, X. Wang, Y. Cao, et al. Brusatol reverses lipopolysaccharide-induced epithelial-mesenchymal transformation and induces apoptosis through PI3K/AKT/NF-кB pathway in human gastric cancer SGC-7901 cells. Anticancer Drugs, 32 (4) (2021), pp. 394-404
|
| [26] |
B.C. Cavalcanti, P.M. da Costa, A.A. Carvalho, F.A.R. Rodrigues, R.C.N. Amorim, E.C.C. Silva, et al. Involvement of intrinsic mitochondrial pathway in neosergeolide-induced apoptosis of human HL-60 leukemia cells: the role of mitochondrial permeability transition pore and DNA damage. Pharm Biol, 50 (8) (2012), pp. 980-993
|
| [27] |
D. Yeo, N. Huynh, J.A. Beutler, C. Christophi, A. Shulkes, G.S. Baldwin, et al. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of p21-activated kinases. Cancer Lett, 346 (2) (2014), pp. 264-272
|
| [28] |
N.N. Win, T. Ito, K.T. Ismail, Y.Y. Win, M. Tanaka, et al. Picrajavanicins A-G, quassinoids from Picrasma javanica collected in Myanmar. J Nat Prod, 78 (12) (2015), pp. 3024-3030
|
| [29] |
Y. Chen, L. Zhu, X. Yang, C. Wei, C. Chen, Y. He, et al. Ailanthone induces G2/M cell cycle arrest and apoptosis of SGC-7901 human gastric cancer cells. Mol Med Rep, 16 (5) (2017), pp. 6821-6827
|
| [30] |
W.CP. Prema, A.E. Nugroho, M.D. Awouafack, Y.Y. Win, N.N. Win, et al. Two new quassinoids and other constituents from Picrasma javanica wood, and their biological activities. J Nat Med, 73 (3) (2019), pp. 589-596
|
| [31] |
N. Dukaew, K. Chairatvit, P. Pitchakarn, A. Imsumran, J. Karinchai, W. Tuntiwechapikul, et al. Inactivation of AKT/NF-κB signaling by eurycomalactone decreases human NSCLC cell viability and improves the chemosensitivity to cisplatin. Oncol Rep, 44 (4) (2020), pp. 1441-1454
|
| [32] |
R. Ye, N. Dai, Q. He, P. Guo, Y. Xiang, Q. Zhang, et al. Comprehensive anti-tumor effect of brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/AKT/mTOR pathway in hepatocellular carcinoma. Biomed Pharmacother, 105 (2018), pp. 962-973
|
| [33] |
S. Guo, J. Zhang, C. Wei, Z. Lu, R. Cai, D. Pan, et al. Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the AKT/mTOR signaling pathway. Cancer Chemother Pharmacol, 85 (6) (2020), pp. 1097-1108
|
| [34] |
J. Chandrasekaran, J. Balasubramaniam, A. Sellamuthu, A. Ravi. An in vitro study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells. J Pharm Pharmacol, 73 (6) (2021), pp. 749-757
|
| [35] |
D. Meng, X. Li, L. Han, L. Zhang, W. An, X. Li. Four new quassinoids from the roots of Eurycoma longifolia Jack. Fitoterapia, 92 (2014), pp. 105-110
|
| [36] |
W.Q. Yang, W. Tang, X.J. Huang, J.G. Song, Y.Y. Li, Y. Xiong, et al. Quassinoids from the roots of Eurycoma longifolia and their anti-proliferation activities. Molecules, 26 (19) (2021), p. 5939
|
| [37] |
B. Tan, Y. Huang, L. Lan, B. Zhang, L. Ye, W. Yan, et al. Bruceine D induces apoptosis in human non-small cell lung cancer cells through regulating JNK pathway. Biomed Pharmacother, 117 (2019), Article 109089
|
| [38] |
C.D. Mohan, Y.Y. Liew, Y.Y. Jung, S. Rangappa, H.D. Preetham, A. Chinnathambi, et al. Brucein D modulates MAPK signaling cascade to exert multi-faceted anti-neoplastic actions against breast cancer cells. Biochimie, 182 (2021), pp. 140-151
|
| [39] |
R. Huang, L. Zhang, J. Jin, Y. Zhou, H. Zhang, C. Lv, et al. Bruceine D inhibits HIF-1α-mediated glucose metabolism in hepatocellular carcinoma by blocking ICAT/β-catenin interaction. Acta Pharm Sin B, 11 (11) (2021), pp. 3481-3492
|
| [40] |
Y. Wang, W.J. Wwang, C. Su, D.M. Zhang, L.P. Xu, R.R. He, et al. Cytotoxic quassinoids from Ailanthus altissima. Bioorg Med Chem Lett, 23 (3) (2013), pp. 654-657
|
| [41] |
L. Zhao, Q. Wen, G. Yang, Z. Huang, T. Shen, H. Li, et al. Apoptosis induction of dehydrobruceine B on two kinds of human lung cancer cell lines through mitochondrial-dependent pathway. Phytomedicine, 23 (2) (2016), pp. 114-122
|
| [42] |
J. Xu, D. Xiao, W.W. Song, L. Chen, W.Y. Liu, N. Xie, et al. Quassinoids from the stems of Picrasma quassioides and their cytotoxic and NO production-inhibitory activities. Fitoterapia, 110 (2016), pp. 13-19
|
| [43] |
J.Y. Zhang, M.T. Lin, H.Y. Tung, S.L. Tang, T. Yi, Y.Z. Zhang, et al. Bruceine D induces apoptosis in human chronic myeloid leukemia K 562 cells via mitochondrial pathway. Am J Cancer Res, 6 (4) (2016), pp. 819-826
|
| [44] |
M.E. Issa, S. Berndt, G. Carpentier, J.M. Pezzuto, M. Cuendet. Bruceantin inhibits multiple myeloma cancer stem cell proliferation. Cancer Biol Ther, 17 (9) (2016), pp. 966-975
|
| [45] |
Z. Su, J. Hao, Z. Xu, R. Huang, N. Zhang, S. Qiu. A new quassinoid from fruits of Brucea javanica. Nat Prod Res, 27 (21) (2013), pp. 2016-2021
|
| [46] |
Q.M. Ye, L.L. Bai, S.Z. Hu, H.Y. Tian, L.J. Ruan, Y.F. Tan, et al. Isolation, chemotaxonomic significance and cytotoxic effects of quassinoids from Brucea javanica. Fitoterapia, 105 (2015), pp. 66-72
|
| [47] |
Z. Zhuo, J. Hu, X. Yang, M. Chen, X. Lei, L. Deng, et al. Ailanthone inhibits Huh 7 cancer cell growth via cell cycle arrest and apoptosis in vitro and in vivo. Sci Rep, 5 (1) (2015), p. 16185
|
| [48] |
L. Liu, Z.X. Lin, P.S. Leung, L.H. Chen, M. Zhao, J. Liang. Involvement of the mitochondrial pathway in bruceine D-induced apoptosis in Capan-2 human pancreatic adenocarcinoma cells. Int J Mol Med, 30 (1) (2012), pp. 93-99
|
| [49] |
X.L. Yang, Y.L. Yuan, D.M. Zhang, F. Li, W.C. Ye. Shinjulactone O, a new quassinoid from the root bark of Ailanthus altissima. Nat Prod Res, 28 (18) (2014), pp. 1432-1437
|
| [50] |
Z. Lu, Z.Q. Lai, A.W.N. Leung, P.S. Leung, Z.S. Li, Z.X. Lin. Exploring brusatol as a new anti-pancreatic cancer adjuvant: biological evaluation and mechanistic studies. Oncotarget, 8 (49) (2017), pp. 84974-84985
|
| [51] |
C. Lu, L. Fan, P.F. Zhang, W.W. Tao, C.B. Yang, E.X. Shang, et al. A novel P38α MAPK activator bruceine A exhibits potent anti-pancreatic cancer activity. Comput Struct Biotechnol J, 19 (2021), pp. 3437-3450
|
| [52] |
J.P. Evans, B.K. Winiarski, P.A. Sutton, R.P. Jones, L. Ressel, C.A. Duckworth, et al. The Nrf 2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. Oncotarget, 9 (43) (2018), pp. 27104-27116
|
| [53] |
D. Ren, N.F. Villeneuve, T. Jiang, T. Wu, A. Lau, H.A. Toppin, et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci USA, 108 (4) (2011), pp. 1433-1438
|
| [54] |
Z. Xiao, C.S. Ching, C.H. Li, S.C. Tang, S.K.W. Tsui, Z. Lin, et al. Role of microRNA-95 in the anticancer activity of Brucein D in hepatocellular carcinoma. Eur J Pharmacol, 728 (2014), pp. 141-150
|
| [55] |
G. Robert, V. Jullian, A. Jacquel, C. Ginet, M. Dufies, S. Torino, et al. Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway. Oncotarget, 3 (12) (2012), pp. 1688-1699
|
| [56] |
M. Wang, G. Shi, C. Bian, M.F. Nisar, Y. Guo, Y. Wu, et al. UVA irradiation enhances brusatol-mediated inhibition of melanoma growth by downregulation of the Nrf2-mediated antioxidant response. Oxid Med Cell Longev, 2018 (2018), p. 9742154
|
| [57] |
C.M. Wang, H.F. Li, X.K. Wang, W. Li, Q. Su, X. Xiao, et al. Ailanthus Altissima-derived ailanthone enhances gastric cancer cell apoptosis by inducing the repression of base excision repair by downregulating p23 expression. Int J Biol Sci, 17 (11) (2021), pp. 2811-2825
|
| [58] |
Z. Wu, Y. Xu, J. Xu, J. Lu, L. Cai, Q. Li, et al. Brusatol inhibits tumor growth and increases the efficacy of cabergoline against pituitary adenomas. Oxid Med Cell Longev, 2021 (2021), p. 6696015
|
| [59] |
X. Liu, H. Xu, Y. Zhang, P. Wang, W. Gao. Brusatol inhibits amyloid-β-induced neurotoxicity in U-251 cells via regulating the Nrf2/HO-1 pathway. J Cell Biochem, 120 (6) (2019), pp. 10556-10563
|
| [60] |
Y. Xiang, W. Ye, C. Huang, B. Lou, J. Zhang, D. Yu, et al. Brusatol inhibits growth and induces apoptosis in pancreatic cancer cells via JNK/p 38 MAPK/NF-κB/Stat3/Bcl-2 signaling pathway. Biochem Biophys Res Commun, 487 (4) (2017), pp. 820-826
|
| [61] |
J.H. Lee, S. Rangappa, C.D. Mohan, S.G. Basappa, Z.X. Lin, et al. Brusatol, a Nrf 2 inhibitor targets STAT3 signaling cascade in head and neck squamous cell carcinoma. Biomolecules, 9 (10) (2019), p. 550
|
| [62] |
R. Wang, Q. Xu, L. Liu, X. Liang, L. Cheng, M. Zhang, et al. Antitumour activity of 2-dihydroailanthone from the bark of Ailanthus altissima against U251. Pharm Biol, 54 (9) (2016), pp. 1641-1648
|
| [63] |
S. Hajjouli, S. Chateauvieux, M.H. Teiten, B. Orlikova, M. Schumacher, M. Dicato, et al. Eurycomanone and eurycomanol from Eurycoma longifolia Jack as regulators of signaling pathways involved in proliferation, cell death and inflammation. Molecules, 19 (9) (2014), pp. 14649-14666
|
| [64] |
P.F. Wong, W.F. Cheong, M.H. Shu, C.H. Teh, K.L. Chan, S. AbuBakar. Eurycomanone suppresses expression of lung cancer cell tumor markers, prohibitin, annexin 1 and endoplasmic reticulum protein 28. Phytomedicine, 19 (2) (2012), pp. 138-144
|
| [65] |
M.H. Kang, C.P. Reynolds. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res, 15 (4) (2009), pp. 1126-1132
|
| [66] |
S.J. Cai, Y. Liu, S. Han, C. Yang. Brusatol, an NRF2 inhibitor for future cancer therapeutic. Cell Biosci, 9 (1) (2019), p. 45
|
| [67] |
Y. Pei, N. Hwang, F. Lang, L. Zhou, J.H. Wong, R.K. Singh, et al. Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3Kγ isoform. Commun Biol, 3 (1) (2020), p. 267
|
| [68] |
H. Li, H. Zhu, C.J. Xu, J. Yuan. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94 (4) (1998), pp. 491-501
|
| [69] |
H. Urra, E. Dufey, T. Avril, E. Chevet, C. Hetz. Endoplasmic reticulum stress and the hallmarks of cancer. Trends Cancer, 2 (5) (2016), pp. 252-262
|
| [70] |
S.D. Shnyder, J.E. Mangum, M.J. Hubbard. Triplex profiling of functionally distinct chaperones (ERp29/PDI/BiP) reveals marked heterogeneity of the endoplasmic reticulum proteome in cancer. J Proteome Res, 7 (8) (2008), pp. 3364-3372
|
| [71] |
Y.P. Yang, M. Li, B. Xu, G. Wei, J.R. Cui, K. Wang. Allicin induces apoptosis, cell cycle arrest and microtubule disassembly in human nasopharyngeal carcinoma KB cells. J Chin Pharm Sci, 18 (2) (2009), pp. 114-120
|
| [72] |
K. Vermeulen, D.R. Van Bockstaele, Z.N. Berneman. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif, 36 (3) (2003), pp. 131-149
|
| [73] |
S. Lamouille, J. Xu, R. Derynck. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol, 15 (3) (2014), pp. 178-196
|
| [74] |
J. Seo, J. Ha, E. Kang, H. Yoon, S. Lee, S.Y. Ryu, et al. Anti-cancer effects of glaucarubinone in the hepatocellular carcinoma cell line Huh7 via regulation of the epithelial-to-mesenchymal transition-associated transcription factor twist1. Int J Mol Sci, 22 (4) (2021), p. 1700
|
| [75] |
Y. Xiang, W. Ye, C. Huang, D. Yu, H. Chen, T. Deng, et al. Brusatol enhances the chemotherapy efficacy of gemcitabine in pancreatic cancer via the Nrf 2 signalling pathway. Oxid Med Cell Longev, 2018 (2018), p. 2360427
|
| [76] |
Y. Murakami, K. Sugiyama, H. Ebinuma, N. Nakamoto, K. Ojiro, P. Chu, et al. Dual effects of the Nrf 2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells. BMC Cancer, 18 (1) (2018), p. 680
|
| [77] |
H.M. Chen, Z.Q. Lai, H.J. Liao, J.H. Xie, Y.F. Xian, Y.L. Chen, et al. Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells. Int J Mol Med, 41 (3) (2018), pp. 1447-1454
|
| [78] |
Z. Huang, G. Yang, T. Shen, X. Wang, H. Li, D. Ren. Dehydrobruceine B enhances the cisplatin-induced cytotoxicity through regulation of the mitochondrial apoptotic pathway in lung cancer A549 cells. Biomed Pharmacother, 89 (2017), pp. 623-631
|
| [79] |
S. Karthikeyan, S.L. Hoti, Y. Nazeer, H.V. Hegde. Glaucarubinone sensitizes KB cells to paclitaxel by inhibiting ABC transporters via ROS-dependent and p53-mediated activation of apoptotic signaling pathways. Oncotarget, 7 (27) (2016), pp. 42353-42373
|
| [80] |
J.D. Hayes, M. Mcmahon. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci, 34 (4) (2009), pp. 176-188
|
| [81] |
A. Lau, N.F. Villeneuve, Z. Sun, P. Wong, D. Zhang. Dual roles of Nrf2 in cancer. Pharmacol Res, 58 (5-6) (2008), pp. 262-270
|
| [82] |
D.D. Zhang. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev, 38 (4) (2006), pp. 769-789
|
| [83] |
T.W. Kensler, N. Wakabayashi, S. Biswal. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol, 47 (1) (2007), pp. 89-116
|
| [84] |
A. Verma, K. Mehta. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat, 10 (4-5) (2007), pp. 144-151
|
| [85] |
T. Mashima, T. Tsuruo. Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist Updat, 8 (6) (2005), pp. 339-343
|
| [86] |
Y. He, S. Peng, J. Wang, H. Chen, X. Cong, A. Chen, et al. Ailanthone targets p 23 to overcome MDV3100 resistance in castration-resistant prostate cancer. Nat Commun, 7 (1) (2016), p. 13122
|
| [87] |
X. Sun, Q. Wang, Y. Wang, L. Du, C. Xu, Q. Liu. Brusatol enhances the radiosensitivity of A549 cells by promoting ROS production and enhancing DNA damage. Int J Mol Sci, 17 (7) (2016), p. 997
|
| [88] |
J. Zhang, X. Fang, Z. Li, H.F. Chan, Z. Lin, Y. Wang, et al. Redox-sensitive micelles composed of disulfide-linked Pluronic-linoleic acid for enhanced anticancer efficiency of brusatol. Int J Nanomedicine, 13 (2018), pp. 939-956
|
| [89] |
W. Tao, N. Wang, J. Ruan, X. Cheng, L. Fan, P. Zhang, et al. Enhanced ROS-boosted phototherapy against pancreatic cancer via Nrf2-mediated stress-defense pathway suppression and ferroptosis induction. ACS Appl Mater Interfaces, 14 (5) (2022), pp. 6404-6416
|
| [90] |
W. Tao, X. Cheng, D. Sun, Y. Guo, N. Wang, J. Ruan, et al. Synthesis of multi-branched Au nanocomposites with distinct plasmon resonance in NIR-II window and controlled CRISPR-Cas 9 delivery for synergistic gene-photothermal therapy. Biomaterials, 287 (2022), Article 121621
|
PDF(3146 KB)
